# High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation

> **NCT02404675** · PHASE4 · UNKNOWN · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** icotinib

## Key facts

- **NCT ID:** NCT02404675
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2017-12
- **Final completion:** 2018-09
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404675, "High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02404675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*